Menu Search
Equities

Intra-Cellular Therapies Inc

23I:BRN

Intra-Cellular Therapies Inc

Actions
  • Price (CHF)61.86
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 04 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Intra-Cellular Therapies Inc grew revenues 85.51% from 250.31m to 464.37m while net income improved from a loss of 256.26m to a smaller loss of 139.67m.
Gross margin92.30%
Net profit margin-14.07%
Operating margin-19.82%
Return on assets-8.46%
Return on equity-9.90%
Return on investment-9.74%
More ▼

Cash flow in USDView more

In 2023, Intra-Cellular Therapies Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 105.54m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 124.20m for operations while cash generated from financing totalled 17.81m.
Cash flow per share-0.8527
Price/Cash flow per share--
Book value per share10.80
Tangible book value per share10.80
More ▼

Balance sheet in USDView more

Intra-Cellular Therapies Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio7.66
Quick ratio7.51
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.